You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Novel Ultra-Flexible Hybrid Circuits for Intraocular Retinal Prostheses

    SBC: PREMITEC, INC.            Topic: N

    DESCRIPTION provided by applicant Retinal prosthetic devices currently under development are designed to bypass the non functioning portion of the visual pathway photoreceptor layer in individuals suffering from diseases including retinitis pigmentosa RP and age related macular degeneration AMD Current devices enable patients to only see object positions and read large letters and furth ...

    STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Clinical Development of a Therapeutic Agent for COPD

    SBC: BIOMARCK PHARMACEUTICALS, LTD            Topic: NHLBI

    DESCRIPTION provided by applicant Hypersecretion of mucus into the respiratory airways is a major contributing factor in several lung diseases including chronic pulmonary disease COPD asthma cystic fibrosis allergic rhinitis and bronchiectasis Despite the obvious medical importance there presently are no effective therapies to control excess mucus secretion in these diseases and very ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Improved diagnostic and monitoring assays for thyroid cancer

    SBC: Soymeds Inc            Topic: NCI

    DESCRIPTION provided by applicant Thyroid cancer is the most common type of endocrine malignancy New thyroid cancers patients are identified daily and most patients live for decades following diagnosis Thyroglobulin TG levels in the sera or in fine needle biopsies of thyroid cancer patients are routinely quantified using various agency approved e g FDA immunoassays for diagnostic and p ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Novel Manufacturing Processes for Tissue Engineered Vascular Grafts

    SBC: HUMACYTE, INC.            Topic: NHLBI

    DESCRIPTION provided by applicant This Phase IIB SBIR application is responsive to NHLBI RFA HL andquot NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart Lung Blood and Sleep Disorders and Diseases R andquot This RFA solicits work on andquot basic applied and clinical research on all product and service development related to the ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  5. IRT-based Self-report Screener for Prodromal Schizophrenia & Early Psychosis

    SBC: Health Outcomes Inc            Topic: NIMH

    DESCRIPTION provided by applicant Schizophrenia is one of the most debilitating and costly mental illnesses in the United States with peak incidence in individuals aged and causing annual direct and indirect costs of over $ billion Wu et al Several studies suggest that early identification and treatment can delay onset and decrease the severity of schizophrenia leading to a significant reduction i ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Context Understanding Technology to improve internet accessibility for users with

    SBC: VORTANT TECHNOLOGIES, LLC            Topic: NEI

    DESCRIPTION provided by applicant The purpose of this SBIR project is to develop a new tool to improve the ability of blind and visually impaired people to quickly get to the right web pages to avoid ending up on the wrong web pages and to reach the desired part of each web page efficiently The motivation for this effort is that getting a andapos big pictureandapos understanding of a web page is o ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Osteochondral tissue repair in an ovine model using a 3D woven poly (e-caprolacto

    SBC: Cytex Therapeutics, Inc.            Topic: NIA

    DESCRIPTION (provided by applicant): Standard microfracture is a first-line, widely used and cost-effective surgical technique for repairing damaged articular cartilage, but, it is limited by decreased long-term efficacy and limited applicability in largerlesions. This leads to a burgeoning economic burden associated with primary and follow-up treatment costs, estimated at more than 40 billion dol ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Controlling mechanical signal transduction to treat osteoarthritis

    SBC: Cytex Therapeutics, Inc.            Topic: NIA

    DESCRIPTION (provided by applicant): Controlling mechanical signal transduction to treat osteoarthritis Abstract The TRPV4 calcium (Ca++) permeable ion channel has been shown to be expressed and functional in chondrocytes, the cells responsible for the maintenance of cartilage in weight-bearing joints. Trauma of joints with subsequent damage of cartilage, as well as chronically increased joint loa ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Evaluation of a new class of molecules for treating MRSA infective endocarditis

    SBC: AGILE SCIENCES, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Patients with infective endocarditis (IE) have a poor prognosis with one third of the patients succumbing to the infection within the first year. Treatments for endocarditis involve antibiotic therapy and/or surgery that cost upwards of 100,000 per patient; however, many cases do not respond to the antibiotic treatment and surgery poses high risks. Cases of en ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Biomarker discovery for immunodiagnosis of invasive candidiasis

    SBC: DxDiscovery Incorporated            Topic: NIAID

    DESCRIPTION (provided by applicant): Invasive candidiasis (IC) is one of the most serious threats to patients in a critical setting. With as many as 60,000 cases per year in the U.S., the total cost associated with IC in the U.S. may be as high as 2-4 billion/year. One of the most critical factors influencing patient outcome is early diagnosis. The goal of this project is a rapi and inexpensive i ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government